CCBP samples as of 05/31/2026. Using plasma and parkinsonian disorders as an example, the table should be interpreted as follow: currently, 741 patients have a parkinsonian disorder and at least one stored plasma aliquot sample (plasma typically stored in 6-8 aliquots), 423 patients have at least two stored plasma samples (all separated by at least one year, per our study design), and 331 patients have at least two stored plasma samples separated by at least 2.5 years. Any samples collected on the same day are counted as one.
We stopped producing a table showing the number of samples at BL, Y1, Y2, etc., because it doesn’t always reflect the true number of patients with more than one sample. The count of patients with samples three years apart includes a subgroup who have samples at Y3 and beyond. During the first 3 years of CCBP, we collected samples annually, but then shifted to collecting at BL, Y3, Y6, etc. Our first enrolled patients have samples at BL, Y1, Y2 and Y3, while others have samples at BL and Y3.
The diagnosis listed reflects the most recent diagnosis in our database. Because we track diagnoses longitudinally, we can also identify participants who entered the study with a different initial diagnosis.
We store blood in PAXgene tubes for later RNA extraction. Stool samples are collected and stored in OMNIgene-GUT OMR-200 tubes (https://www.dnagenotek.com/us/products/collection-microbiome/omnigene-gut/OMR-200). DNA stored at -20 °C; PBMC extracted immediately upon blood collection and stored in liquid nitrogen at -175 °C; plasma, blood in PAXgene tubes, urine, stool samples, and CSF are stored at -80 °C.
• Parkinsonian disorders include Parkinson’s, dementia with Lewy bodies, Parkinson’s disease dementia, multiple system atrophy, progressive supranuclear palsy, and other parkinsonian disorders (see below).
• Dementia disorders include Alzheimer’s, Parkison’s disease dementia, dementia with Lewy bodies, progressive supranuclear palsy, frontotemporal dementia, corticobasal syndrome, autopsy-confirmed corticobasal degeneration, high-order gait disorder, normal pressure hydrocephalus, leukoencephalopathy, and neurodegenerative dementia disorders under investigation.
• Among other parkinsonian disorders, the cohort includes 3 patients with primary progressive freezing of gait, 2 with corticobasal syndrome, 1 with autopsy-confirmed corticobasal degeneration, 1 with pallidoluysian atrophy, and 29 with neurodegenerative parkinsonian disorders under investigation.
• Among tremor disorders, there are 16 patients with essential tremor, 16 with dystonic tremor, 3 with isolated tremor, 2 with isolated action tremor, and one each with isolated action-and-rest tremor, isolated rest tremor, and orthostatic tremor.
